Agios Pharmaceuticals, Inc. (AGIO) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2025
Loading P/E history...
AGIO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Agios Pharmaceuticals, Inc. (AGIO) trades at a price-to-earnings ratio of -3.9x, with a stock price of $27.53 and trailing twelve-month earnings per share of $-7.19.
The current P/E is 250% below its 5-year average of 2.6x. Over the past five years, AGIO's P/E has ranged from a low of 1.5x to a high of 3.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, AGIO trades at a 117% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, AGIO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AGIO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AGIO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 8.3Lowest | -Best | +264%Best | |
| $10B | 30.1 | -Best | -19% | |
| $39B | 127.0 | -Best | +207% | |
| $9B | 43.4 | -Best | +128% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
AGIO Historical P/E Data (2021–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $33.26 | $11.05 | 3.0x | +17% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $29.30 | $11.29 | 2.6x | +1% |
| FY2024 Q4 | $32.86 | $11.39 | 2.9x | +12% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $44.43 | $11.36 | 3.9x | +52% |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $32.87 | $22.24 | 1.5x | -43% |
| FY2021 Q3 | $46.15 | $22.57 | 2.0x | -21% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $55.11 | $22.70 | 2.4x | -6% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $51.64 | $22.80 | 2.3x | -12% |
Average P/E for displayed period: 2.6x
See AGIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AGIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AGIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAGIO — Frequently Asked Questions
Quick answers to the most common questions about buying AGIO stock.
Is AGIO stock overvalued or undervalued?
AGIO trades at -3.9x P/E, below its 5-year average of 2.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does AGIO's valuation compare to peers?
Agios Pharmaceuticals, Inc. P/E of -3.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is AGIO's PEG ratio?
AGIO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2025.